-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 OUsU4UE2W4GpwvJf7rKKb95YUwORu4jpbcvho+VVDWCcv2jqsE7wXNYXqRAtx5NS
 d32l4yMcEuNJQMMnCteA+Q==

<SEC-DOCUMENT>0000890163-08-000370.txt : 20080516
<SEC-HEADER>0000890163-08-000370.hdr.sgml : 20080516
<ACCEPTANCE-DATETIME>20080516105842
ACCESSION NUMBER:		0000890163-08-000370
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20080515
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20080516
DATE AS OF CHANGE:		20080516

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PIPEX PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133808303
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12584
		FILM NUMBER:		08840706

	BUSINESS ADDRESS:	
		STREET 1:		3985 RESEARCH PARK DRIVE
		CITY:			ANN ARBOR
		STATE:			MI
		ZIP:			48108
		BUSINESS PHONE:		734-332-7800

	MAIL ADDRESS:	
		STREET 1:		3985 RESEARCH PARK DRIVE
		CITY:			ANN ARBOR
		STATE:			MI
		ZIP:			48108

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SHEFFIELD PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19970730

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SHEFFIELD MEDICAL TECHNOLOGIES INC
		DATE OF NAME CHANGE:	19940606
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>s11-8442_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE> </TITLE>
</HEAD>
<BODY bgcolor="#ffffff">




<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><b><font SIZE=2>UNITED STATES</font></b></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><b><font SIZE=2>SECURITIES AND EXCHANGE COMMISSION</font></b></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><b><font SIZE=2>WASHINGTON, D.C. 20549</font></b></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><b><font SIZE=3>FORM 8-K</font></b></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><b><font SIZE=2>CURRENT REPORT</font></b></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><b><font size=2>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</font></b></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><font size=2>Date of Report (date of earliest event reported): May 15, 2008</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><b><font size=5>Pipex Pharmaceuticals, Inc.</font></b></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><font size=2>(Exact name of registrant as specified in charter)</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><b><font size=2>Delaware</font></b></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><font size=2>(State or other jurisdiction of incorporation)</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><font size=2>&nbsp;</font></p>


<table border="0" cellspacing=0 cellpadding=0 width="103%" style='border-collapse:collapse'>
    <tr >
        <td width="48%" valign=top >
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=2>01-12584 &nbsp;</font></p>
<p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=2>(Commission File Number)</font></p> </td>
        <td width="51%" valign=top >
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=2>13-3808303 &nbsp;</font></p>
<p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=2>(IRS Employer Identification No.)</font></p> </td> </tr></table>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><b><font size=2>3930 Varsity Drive</font></b></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><b><font size=2>Ann Arbor, MI 48108</font></b></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><b><font size=2>______________________________</font></b></p>

<p style=' margin-bottom:0pt; margin-top:8.5pt;text-align:center;'><font size=2>(Address of principal executive offices and zip code)</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><font size=2>(734) 332-7800</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><b><font size=2>______________________________</font></b></p>

<p style=' margin-bottom:0pt; margin-top:8.5pt;text-align:center;'><font size=2>&nbsp; &nbsp; (Registrant&#146;s telephone number including area code)</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><font SIZE=2>N/A</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><b><font size=2>______________________________</font></b></p>

<p style=' margin-bottom:0pt; margin-top:8.5pt;text-align:center;'><font size=2>(Former Name and Former Address)</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt; text-indent:0.5in;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt; text-indent:0.5in;text-align:left;'><font size=2>Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>


<table border="0" cellspacing=0 cellpadding=0 width="123%" style='border-collapse:collapse'>
    <tr >
        <td width="7%" valign=top >
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=2>&nbsp;</font></p> </td>
        <td width="7%" valign=top >
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font face=Wingdings>o</font></p> </td>
        <td width="85%" valign=top >
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=2>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></p> </td> </tr></table>

<p style=' margin-bottom:0pt; margin-top:0pt; margin-left:0.5in; text-indent:-0.5in;text-align:left;'><font size=2>&nbsp;</font></p>


<table border="0" cellspacing=0 cellpadding=0 width="123%" style='border-collapse:collapse'>
    <tr >
        <td width="7%" valign=top >
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=2>&nbsp;</font></p> </td>
        <td width="7%" valign=top >
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font face=Wingdings>o</font></p> </td>
        <td width="85%" valign=top >
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=2>Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)</font></p> </td> </tr></table>

<p style=' margin-bottom:0pt; margin-top:0pt; margin-left:0.5in; text-indent:-0.5in;text-align:left;'><font size=2>&nbsp;</font></p>


<table border="0" cellspacing=0 cellpadding=0 width="123%" style='border-collapse:collapse'>
    <tr >
        <td width="7%" valign=top >
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=2>&nbsp;</font></p> </td>
        <td width="7%" valign=top >
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font face=Wingdings>o</font></p> </td>
        <td width="85%" valign=top >
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=2>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))&nbsp;</font></p> </td> </tr></table>

<p style=' margin-bottom:0pt; margin-top:0pt; margin-left:0.5in; text-indent:-0.5in;text-align:left;'><font size=2>&nbsp;</font></p>


<table border="0" cellspacing=0 cellpadding=0 width="123%" style='border-collapse:collapse'>
    <tr >
        <td width="7%" valign=top >
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=2>&nbsp;</font></p> </td>
        <td width="7%" valign=top >
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font face=Wingdings>o</font></p> </td>
        <td width="85%" valign=top >
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=2>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></p> </td> </tr></table>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:8.5pt;text-align:center;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>
<br>
<HR noshade align="center" width="100%" size="2">
<p style='page-break-before:always'></p>
<pAGE>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><b><font size=2>Item 2.02 &#150; Results of Operations and Financial Condition.</font></b></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt; text-indent:0.5in;text-align:left;'><font size=2>On May 15, 2008, Pipex Pharmaceuticals, Inc., a Delaware corporation (the &#147;Registrant") issued the attached press release that included financial information for its first quarter ended March 31, 2008. A copy of the press release is attached as Exhibit 99.1 to this Report on Form 8-K. The information contained in the press release is being furnished to the Commission and shall not be deemed incorporated by reference into any of the Registrant&#146;s registration statements or other filings with the Commission.  </font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>&nbsp;</font></p>


<table border="0" cellspacing=0 cellpadding=0 width="281" style='border-collapse:collapse'>
    <tr >
        <td width="100%" valign=top >
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><b><font size=2>Item 9.01 </font></b><font size=2>&nbsp;</font><b><font size=2> Financial Statements and Exhibits.</font></b></p> </td> </tr></table>

<p style=' margin-bottom:0pt; margin-top:0pt; text-indent:0.5in;text-align:left;'><font size=2>&nbsp;</font></p>


<table border="0" cellspacing=0 cellpadding=0 width="95" style='margin-left:.5in;border-collapse:collapse'>
    <tr >
        <td width="28%" valign=top >
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=2>(d)</font></p> </td>
        <td width="71%" valign=top >
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=2>Exhibits.  </font></p> </td> </tr></table>

<p style=' margin-bottom:0pt; margin-top:0pt; margin-left:0.5in;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt; margin-left:0.77in;text-align:left;'><font size=2>Exhibit 99.1 Press Release issued by Pipex Pharmaceuticals, Inc. dated May 15, 2008.</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt; margin-left:0.77in;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'>
</p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>
<br>
<HR noshade align="center" width="100%" size="2">
<p style='page-break-before:always'></p>
<pAGE>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><font SIZE=2>SIGNATURES</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>


<table border="0" cellspacing=0 cellpadding=0 width="503" style='border-collapse:collapse'>
    <tr >
        <td width="66%" valign=top >
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=2>Dated:  May 15, 2008</font></p> </td>
        <td width="33%" valign=top >
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><u><font size=2>Pipex Pharmaceuticals, Inc.</font></u></p> </td> </tr></table>

<p style=' margin-bottom:0pt; margin-top:0pt; margin-left:2.62in; text-indent:0.88in;text-align:left;'><font size=2>(Registrant)</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>


<table border="0" cellspacing=0 cellpadding=0 width="149" style='margin-left:3.5in;border-collapse:collapse'>
    <tr >
        <td width="100%" valign=top >
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=2>By:&nbsp; </font><u><font size=2>/s/ Steve H. Kanzer&nbsp;&nbsp;</font></u></p> </td> </tr></table>

<p style=' margin-bottom:0pt; margin-top:0pt; margin-left:2.38in; text-indent:1.12in;text-align:left;'><font size=2>Name: Steve H. Kanzer</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt; margin-left:3in; text-indent:0.5in;text-align:left;'><font size=2>Title: Chief Executive Officer</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'>
</p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>
<br>
<HR noshade align="center" width="100%" size="2">
<p style='page-break-before:always'></p>
<pAGE>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><b><font SIZE=2>EXHIBIT INDEX</font></b></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>


<table border="0" cellspacing=0 cellpadding=0 width="212" style='border-collapse:collapse'>
    <tr >
        <td width="67%" valign=top >
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><u><font size=2>Exhibit No</font></u><font size=2>.</font></p> </td>
        <td width="32%" valign=top >
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><u><font size=2>Exhibits.</font></u></p> </td> </tr></table>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>


<table border="0" cellspacing=0 cellpadding=0 width="551" style='border-collapse:collapse'>
    <tr >
        <td width="26%" valign=top >
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=2>99.1</font></p> </td>
        <td width="73%" valign=top >
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=2>Press Release issued by Pipex Pharmaceuticals, Inc. dated May 15, 2008</font></p> </td> </tr></table>

<p style=' margin-bottom:0pt; margin-top:0pt; margin-left:1in; text-indent:0.5in;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>


<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>



</BODY>
</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>s11-8442_ex99.htm
<DESCRIPTION>EXHIBIT 99
<TEXT>
<HTML>
<HEAD>
<TITLE> </TITLE>
</HEAD>
<BODY bgcolor="#ffffff">




<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><img src="intimg1.jpg"><br> </p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:right;'><b><font size=2>Exhibit 99</font></b></p>

<p style=' margin-bottom:3pt; margin-top:12pt;text-align:center;'><b><font size=5>Pipex Pharmaceuticals Announces Clinical Update and First Quarter 2008 Results</font></b></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><b><font size=2>Conference Call Thursday, May 15, 2008 at 4:30 p.m. EST</font></b></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>Ann Arbor, Michigan, May 15, 2008 -- Pipex Pharmaceuticals, Inc. (AMEX: PP), a specialty pharmaceutical company developing innovative late-stage drug candidates for the treatment of neurologic and autoimmune diseases, today announced its clinical update and results for its first quarter of 2008. </font></p>

<p style=' margin-bottom:5pt; margin-top:5pt;text-align:justify;'><font size=2>A conference call has been scheduled for 4:30pm EST today.  In order to participate in the conference call, please call toll free: 800-355-4959 and international dial-in: 416-695-6622.  A replay of the conference call will be archived for at least 15 days on Pipex&#146;s website at </font><u><font size=2>www.pipexinc.com</font></u><font size=2>. </font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>Recent achievements and accomplishments included:</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>&nbsp;</font></p>


<table border="0" cellspacing=0 cellpadding=0 width="100%" style='border-collapse:collapse'>
    <tr >
        <td width="17%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=2>&#9679;</font></p> </td>
        <td width="82%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=2>Completion of submission, peer review and acceptance of manuscript describing results of the Z-Monocys (oral zinc-monocysteine) 80-patient, double-masked, placebo-controlled clinical trial in the treatment of Dry Age Related Macular Degeneration (AMD).</font></p>
<p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=1>&nbsp;</font></p> </td> </tr>
    <tr >
        <td width="17%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=2>&#9679;</font></p> </td>
        <td width="82%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=2>Received FDA approval of clinical investigator&#146;s IND application to initiate a Phase II clinical trial with oral flupirtine (EFFIRMA) for the treatment of fibromyalgia.</font></p>
<p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=1>&nbsp;</font></p> </td> </tr>
    <tr >
        <td width="17%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=2>&#9679;</font></p> </td>
        <td width="82%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=2>Received FDA and IRB approvals to expand enrollment criteria for Phase II/III clinical trial of TRIMESTA for multiple sclerosis to now include patients that may have been previously treated with other agents.</font></p>
<p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=1>&nbsp;</font></p> </td> </tr>
    <tr >
        <td width="17%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=2>&#9679;</font></p> </td>
        <td width="82%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=2>Entered into preliminary supply agreement with a cGMP medical device manufacturer and improved the commercial manufacturing process of the disposable assay component of our FreeBound investigational medical device for the direct measurement of free copper levels in serum and whole blood.</font></p>
<p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=1>&nbsp;</font></p> </td> </tr></table>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>
<br>
<HR noshade align="center" width="100%" size="2">
<p style='page-break-before:always'></p>
<pAGE>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt; margin-left:1in;text-align:justify;'><font size=2>&nbsp;</font></p>


<table border="0" cellspacing=0 cellpadding=0 width="100%" style='border-collapse:collapse'>
    <tr >
        <td width="17%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=2>&#9679;</font></p> </td>
        <td width="82%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=2>Implemented significant cost reduction measures including a 54% reduction in headcount and additional reductions in outside consultants and consulting expenses.</font></p>
<p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=1>&nbsp;</font></p> </td> </tr>
    <tr >
        <td width="17%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=2>&#9679;</font></p> </td>
        <td width="82%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=2>Recently, we received &#147;Orphan Drug&#148; designation from the US FDA for Oral TTM for the treatment of Idiopathic Pulmonary Fibrosis (IPF).</font></p>
<p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=1>&nbsp;</font></p> </td> </tr>
    <tr >
        <td width="17%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=2>&#9679;</font></p> </td>
        <td width="82%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=2>We received a notice of allowance for a U.S. patent for Oral TTM for Alzheimer&#146;s disease.</font></p>
<p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=1>&nbsp;</font></p> </td> </tr></table>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>Steve H. Kanzer, CPA, Esq., Chairman and Chief Executive Officer of Pipex, commented, &#147;We are looking forward to communicating the full breadth of our product pipeline to the investment community, potential pharmaceutical partners and acquirers.  In the near term, we anticipate the full publication of our 80-patient clinical trial results for Z-Monocys for AMD in a peer-reviewed ophthalmology journal.  This composition-of-matter protected conjugated zinc-cysteine complex with improved properties may have wide application in significant disease indications beyond AMD also involving metal dyshomeostasis.  We hope to initiate a Phase II clinical trial using oral flupirtine for the treatment of fibromyalgia by the end of this this quarter.  We are pleased with the increased enrollment rate of the Phase II/III trial of our oral bioidentical estriol candidate TRIMESTA for MS patients, the largest clinical
trial study sponsored by the National Multiple Sclerosis Society for any clinical candidate.&#148;  </font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>Below is a summary of our product candidates and their stages of development:</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><i><b><font size=2>TRIMESTA (oral, once-daily estriol)</font></b></i></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>TRIMESTA, our oral, once-daily bioidentical hormone estriol is currently in a seven U.S. center, placebo-controlled Phase II/III clinical trial which is expected to enroll up to 150 relapsing-remitting Multiple Sclerosis (MS) patients.  TRIMESTA is being supported under a $5 million grant from the Southern California Chapter of the National Multiple Sclerosis Society and NIH. Oral estriol, the active ingredient in TRIMESTA, has been approved throughout Europe and Asia for approximately 40 years but is not available in the U.S.  </font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>This Phase II/III clinical trial builds upon our encouraging results from an earlier single agent Phase IIa clinical trial in female MS patients whereby TRIMESTA demonstrated a 79 percent decrease in MS brain lesions in 3 months (p=0.02) and a 14 percent improvement in cognitive function as measured by the PASAT scoring system at 6 months (p=0.04).  This dataset is also supplemented by a definitive study of the effect of pregnancy on MS, known as the PRIMS (Rate of Pregnancy-related Relapse in Multiple Sclerosis) which was published in the New England Journal of Medicine (NEJM) by </font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>&nbsp;</font></p>
<br>
<HR noshade align="center" width="100%" size="2">
<p style='page-break-before:always'></p>
<pAGE>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>Confavreux et al.  In that study, relapse rates were determined in 254 women with MS during pregnancy and for up to one year after delivery.  Relapse rates were shown to be significantly reduced during the third trimester of pregnancy, by 71 percent (p&#60;0.001).  The relapse rates then increased to 58 percent (p&#60;0.001) during the first three months post-partum before returning to prepregnancy rates.  Together, these data clearly demonstrated that the latter part of pregnancy is associated with a significant reduction in relapses, while there is a rebound increase in relapses post-partum.  Researchers have demonstrated the estriol levels increase to their highest levels during the third trimester, then drop-off to nearly zero during the post-partum period.   </font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><i><b><font size=2>Z-Monocys (oral zinc-monocysteine)</font></b></i></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>We are developing oral Z-monocys as a treatment for dry age-related macular degeneration (&#147;dry AMD&#148;), a disease for which there is no FDA-approved therapy.  Z-monocys has completed a six month, double-masked randomized placebo-controlled trial in 80 dry AMD patients, with statistically significant improvements shown in visual acuity, contrast sensitivity and photorecovery times. A manuscript describing these results has been submitted to a leading peer-reviewed ophthalmic journal, and on May 1, 2008 we were notified that this manuscript has been accepted for publication.  We expect this manuscript describing these clinical trial results to be published shortly.   </font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><i><b><font SIZE=2>EFFIRMA</font></b></i><font size=2> </font><sup><font SIZE=2>TM</font></sup><font size=2> </font><i><b><font size=2>(oral flupirtine)</font></b></i></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>We are developing EFFIRMA, an oral, non-opiate NMDA receptor antagonist with potassium channel modulatory activity for the treatment of fibromyalgia and various pain-related diseases.  Flupirtine, the active ingredient in EFFIRMA, has been commercially approved for over 20 years in various countries in Europe for the treatment of pain and has been used by over 1.5 million patients.  Additionally, flupirtine has been tested in 2,775 patients in controlled clinical trial studies.  </font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>Oral flupirtine has recently received an IND with the FDA to conduct a Phase II clinical trial with EFFIRMA in fibromyalgia patients.&nbsp;&nbsp; We plan to fund this double-blind placebo-controlled Phase II clinical study which is designed to enroll up to 90 patients with fibromyalgia.  </font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><i><b><font size=2>Oral TTM</font></b><font size=2> </font><b><font size=2>(oral tetrathiomolybdate)</font></b></i></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>We are developing oral tetrathiomolybdate (oral TTM), an anti-copper therapeutic compound, for the treatment of various diseases in which there is an elevated level of &#147;free&#148; copper.  We continue to consider the potential use of oral TTM in the treatment of Alzheimer&#146;s disease, Idiopathic Pulmonary Fibrosis (IPF) and Huntington&#146;s disease, all diseases of copper dyshomeostatis.  We recently received an &#147;Orphan Drug&#148; designation from the FDA for the treatment of IPF with oral TTM.  We continue to make progress with evaluating the chemistry, manufacturing and controls issues (CMC) relating to identity, strength and purity of oral TTM.</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>
<br>
<HR noshade align="center" width="100%" size="2">
<p style='page-break-before:always'></p>
<pAGE>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><b><font size=2>Financial Results for First Quarter 2008:</font></b></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>At March 31, 2008, Pipex had cash of approximately $8.8 million, compared to approximately $11.5 million at December 31, 2007. The decrease of approximately $2.7 million during the first quarter of 2008 is attributable to net cash used in operations of approximately $1.8 million, and $900,000 that we elected to use to repay our outstanding equipment notes payable in full in order to eliminate further monthly interest payments as well as the security interest on our $2.0 million in equipment and leasehold improvements primarily relating to our cGMP pharmaceutical production facility in Ann Arbor, Michigan. </font></p>

<p style=' margin-bottom:5pt; margin-top:5pt;text-align:justify;'><font size=2>The net loss applicable to common shareholders for the quarter ended March 31, 2008 was $3,089,456, or $0.15 per share, compared to a net loss applicable to common shareholders of $15,259,257, or $0.90 per share, for the comparable quarter in 2007, representing a decrease in net loss of $12,169,801.  The decrease is primarily attributable to a non-cash charge of $12,409,722 taken during the first quarter of 2007 related to the acquisition of Effective Pharmaceuticals, Inc.  The total of the non-cash charge was reflected through equal and offsetting adjustments to additional paid-in-capital with no net impact on stockholders&#146; equity.  Research and development expenses increased by $707,497 for the quarter ended March 31, 2008 as compared to the same period last year. The increase primarily related to Pipex&#146;s oral TTM&#153; NDA directed activities, as well as the further development of Pipex&#146;s
other product candidates, TRIMESTA&#153;, anti-CD4 802-2, CORRECTA&#153;, SOLOVAX, Z-monocys and EFFIRMA&#153;. General and administrative expenses decreased by $501,299 for the three months ended March 31, 2008 as compared to the first quarter of 2007 which is primarily due to a decreased in stock-based compensation expense.</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><b><font size=2>Guidance on Current Cash Resources and Expenditures  </font></b></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>We implemented significant downsizing and cost saving measures announced March 11, 2008 in order to preserve our capital.  Given the severance and other trailing expenses associated with such downsizing or discontinued oral TTM NDA activities, the full benefit of our cost reduction measures are being fully realized now in this mid-second quarter of 2008.  Given our current cash balance of approximately $8.2 million as of today May 15, 2008, we expect our cash reserves to be sufficient to fund currently planned business operations for the next 15-18 months.  This guidance does not include any potential other major transactions, including corporate partnerships, and, should such an event or events occur this year, financial expectations could change significantly.</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><b><font size=2>About Pipex Pharmaceuticals, Inc. </font></b></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>Pipex Pharmaceuticals, Inc. is a specialty pharmaceutical company that is developing proprietary, late-stage drug candidates for the treatment of neurologic and fibrotic diseases.  Pipex&#146;s strategy is to exclusively in-license proprietary, clinical-stage drug candidates and to complete the further clinical testing, manufacturing and regulatory </font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>&nbsp;</font></p>
<br>
<HR noshade align="center" width="100%" size="2">
<p style='page-break-before:always'></p>
<pAGE>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>requirements and seek marketing authorizations.  Pipex is focused on treating Dry Age Related Macular Degeneration (AMD), multiple sclerosis, fibromyalgia, Alzheimer&#146;s disease, Huntington&#146;s disease, and neurologic Wilson&#146;s disease.  For further information, please visit, </font><u><font size=2>www.pipexinc.com</font></u><font size=2>.  </font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>This release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding Pipex's plans for its product candidates and statements regarding the full publication of an 80 patient, double-blind, placebo controlled clinical trial results for Z-Monocys, and initiating a phase II clinical trial using oral flupirtine for the treatment of fibromyalgia. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "should," and "could," and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Pipex is at an early stage of development and may not ever have any products that
generate significant revenue. Important factors that could cause actual results to differ materially from those reflected in Pipex's forward-looking statements include, among others, a failure of Pipex's product candidates to be demonstrably safe and effective, a failure to obtain regulatory approval for the company's products or to comply with ongoing regulatory requirements, a lack of acceptance of Pipex's product candidates in the marketplace, a failure of the company to become or remain profitable, Pipex's inability to obtain the capital necessary to fund its research and development activities, a loss of any of the company's key scientists or management personnel, and other factors described in Pipex&#146;s report on Form 10-K for the year ended December 31, 2007.  No forward-looking statements can be guaranteed and actual results may differ materially from such statements. The information in this release is provided only as of the date of this release, and Pipex undertakes no
obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>For Further Information Contact:</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>Steve H. Kanzer, CPA, JD</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>Chairman and Chief Executive Officer</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>(734) 332-7800</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>Charles Bisgaier, Ph.D.</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>President</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>(734) 332-7800</font> </p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'>&nbsp;</p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>Redington, Inc. (Investor Relations)</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>Thomas Redington</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>203-222-7399</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><u><font size=2>www.redingtoninc.com</font></u></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'>&nbsp;</p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>


<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'>&nbsp;</p>



</BODY>
</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>intimg1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 intimg1.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!P@'!@H("`@+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!#`0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P``1"`!E`9(#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#V:BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBDH`6BBB@`HI,TM`!245Y=K_B#
M4[75M2CBU:>)(IF5%$B@(.P`Q32N-*YZC2U#:,7M(F8Y+1J2?4XJ6D(6BBB@
M`HHI*`%HI*6@`HI**`%HHHH`****`"BBB@`HHI*`%HI*6@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"D/2EHH`\U\4S3Q
M^);T?:+Y4PFQ8GD"CY1G&.*PVN[T$XNM1QGC+RU[+15<WF_Z^12=CQ@7>H$$
M_:M1QZ^9+0;F^(R;C43C_;EKV>BCF\W^'^0^;R1Y'IVNZO:S#[-JLS,O6&X8
MNGX@\BO1O#NO1ZY9%]GDW$1V3PY^Z?4>Q[51\::9;W&B37I15N;;$B2`8/7E
M2>X-8'A"5HO%"!3@7-LP<8ZE<$'^?YU-VWJ2VKGH=>4>(9)EU756%U*ICG;:
M!C';U%>KUY!XC/\`Q/M4'3]^_-5'3\/S'%7/6;0?Z+$3U,:Y_*LGQF7'AFZ,
M9D#`I@QYW??'IS6O:?\`'G#_`-<U_E4M3LR3QN1[C.(SJ9SZ^;4>;XC'_$Q/
M4X_>FO:**KF\W^'^12E9;'BY6^X.W4.?:6@7%Y;.KM/?6Y)^^9)$_G7M%-EC
M26-DD4,C<%6&0?PHYO-_A_D/G\D<#H7C"]M)88M5E^TVDA"BY;`:+/0MCJ/?
MJ*]`!R`:\NUW38+#6;ZP@1?L[('5,_<W#I],UWOAFX>Z\-Z?-*27:!02>IQQ
MG]*B_<B^I4\3^(QHT4<%NJRWL^3&K'Y44=6;V_G7GE]JNIWLY6XU"YN'/_+.
M-R%_!5K3\23LWB/5;@@DP[(ESV`7/\R36V^_PQX,M[O3?*%U.T9EF=-V_=R?
MP]*I7YK(J+78X@V5YP&L]0XY^Y+2BQO>UE??]^I:W)/&GB*-MIN[5AZBW_\`
MKTS_`(3CQ#_S]6Y_[=__`*]/F7\WX_\``-?>[(R([&Y8YDL=1Y](Y:Z;P5:O
M%XBW?9KR)/L[`F9'`SD?WJJ1^,_$4K8%W;*!_P!,!_C6WX7\0ZKJ.M?9+VY@
MFB\AG_=Q;><COGWHYD[I2O\`/_@&4[WUT.NGR;>3&<[#_*O(8M/E:V02Z=J9
MDQ\Q6*7`->Q45*;2T9)XV^FW>1Y>GZ@5]X9:2*YOM+E'E3WEC*?X6+J6/T;K
M7LM5-4L+;4K"6VN4#(RG!(Y4]B/0BFF^[-.?R.`E\=:M)IHME$:7!.&NE')7
MV7H&_2L(M>:G,SE[V^D'#,N^3'Y=*9;Q"YN+>W+8$LJQ,X/(!8`D?G7LEK:P
MV<"06\:QQ(,*JC`%',_3T')J.R/(UL+I0-^G:GQTVP3?X58M["=;NV\K3]25
MA/'DO%*!C<,YKUNDI)M.]V9MW"EHHH$%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%(>E+24`<HWC^T5W4:;?,$9EW`)@X./[U1GXC6`ZZ
M;?#'7A/_`(JN296=C&K[/,NRF['(!?']:Z5OAPS]=:;G_IV'^-/J]/Q_X`XV
M>Y8/Q&T\?\PZ]_)/_BJ0?$>Q)P--O/K\G_Q55_\`A6[?]!EO_`8?_%4O_"M^
M>=88CT%LO^-'R7WO_(NT#,UWQ5<:[#]D2W^R698,^Y\N^.@/8#-:G@73GFN9
M=892L'E^3;YXWC/S-].`!^-7+'P!IEM(LES+/=D?P.0J$_0=?Q-=2D:QJ%10
MJ@8``P`*1#MT%KR'Q(K'6]48=!.^:]>KDM0\"G4+VZN#JLD0N7+F,0@@9[9S
M37^0)V.HM/\`CSA_ZYK_`"K.U[Q!%H2P-):S7!G8JJQ8R,#/<BM.&/RHDCSG
M:H&?H*Y/QZ,MI8QG]\__`*#2\R7H@/Q$M5X;2KU?KL_^*I#\1[(?\PV\/XI_
MC6'H?AK_`(2+[6S7\MN+>4(%$88'(SFM<?#:(==6E/\`VQ6GZI?>_P#(T7);
M4D'Q'LO^@9>?FG^-07'Q(C92MKI4I<C@S2*%!^@R:?\`\*WB/75I_P#OTM/C
M^&]HK`R:E=,!V157^E._DOO?^0>X<KF]U:_=!B?4;YL97@(/7V4"O5+"SCL+
M"WM(LE(8P@)ZG`ZU5TG0-/T6-ELX2'<?/*YW.WU/]*TA4D.W0\_\::<UCJK:
MEM_T2\`25L?<D`P,^Q%9UIXA%KIPTG4].34[*,@QC=M91U`]#CMTKTZ:".XB
M:*9%DC<89&&01[BN8N?A]I4DC/;RW-J"<[$<,@^@(/\`.A:.XUR]3FQJ_A4C
MY?"7_CZ_XT'6/"PZ>$S_`-]K_C6Z/AU:CKJ5U_WRG^%'_"N;3_H)77_?*?X5
M7,_Z;_R+]SS,0:KX:887PCN]A*O^-;7A:]TB;63%9^'SI\YA+>87!RN1QP?\
MXIP^'ENOW=5NQ_P%/\*T=%\)Q:-?_;$OIYV\LQA9`N`"1Z#VHYN_ZD.W0WI'
MV1LW7:,XKC5^(>^,.NB7)4]#YJ<UV4B[T9>FX8KD5^'L"(J+JUX%7H,)_A4K
M81$?B,BG#:-.#[S)6;J_CF\U&UDM;2U%HDBE6D,F]\'TQP*U_P#A7EH1SJ5V
M?J$_PJ6#X>Z4CAIYKJX`ZJSA5/UV@']:=_3\2_</.\#8/O",G:K@$#([`^HK
MKK'X@WMM"L-[8K=,H`\V.78S>Y!'6NTDTC3Y=/&GO9PFU`P(MN`/IZ'WK`E^
M'FENY:*YNX03D*'5@/;D9J5IM^(^92^(K+\10_W=&F/_`&V6I$\?%IHHWT>6
M,22*FXSJ<9.,TX?#NQ7IJ-Z/H4_PJ:/P)9QRQN;^\?RW5P&*X)!R.U5UUM^)
M#MT.HI:2EI""BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MD-+2$9H`\E4$3QYR/]/Z'_KI7K588\&:$)_.%FP</Y@/FO\`>SG.,^M;@Z4W
M;\Q)6%HHHI#"BBB@`HHHH`*Y#QYR=,P"?WS=/]VNOJAJFBV&LI&E_!YRQG*C
M>RX/X$4":NK'/?#_`#LU3@?\?"_^@BN@UN_DTS29;N+RPR%`#+G:,L%R<=AG
M-+I>C6&C)(EA!Y*RMN<;RV3T[FIK^RCU"T:VE8A&96)'^RP;^E.ZN5&R:N9^
ME:O/>?;T<V\XM<;;BWSY<F03CDGD8YY/45#I_B>'4)=+AB9&ENT+3*%8;,)N
MXS[\5N-$K1-&!M5@1QVS5.+2HHET]1)(?L"[8\D?-\NWG\*=XE7CKH5=1UM[
M+6K2S6.-H'*BXD+8,>\E8\#W88--US69--O+:!;FSM4ECD=I;H$CY=O`P1Z_
MI4MWX<L+XW<EQ'OGN2")BHWQ8`"[#CC!&?K5N73XI[R*YE)8QQ/%M(&&#8SG
M\J?NZ#O'0SI=:O?^$2&K16B"[9%*0N2%8E@H]\'.1]:C;Q(TM[I$-K"K1WH!
MG+$YB!5L`>^58?@:T!I,8TB/3#-*T<>T*Y(W85@0/T`J&#PY9V]P9HVD#&[^
MU8)R`VTC:/1?F)QZFB\1IPU&ZOK;Z=J%I`D<;1N0URS-@QH6"J1_P(_D#4VI
M7US'?6NGV2Q">X5Y#)*"51$QG@$9.6`ZTV\\/:?J$MU+=Q":2X0('903$`.-
MIQQR2?K4EWI?VD6TB74L-U:@A)U`)((PP((P0<#\0*/=T%[NA!?ZE>Z?X?DO
M;B&&*YB(5@26CY<+NXYQ@YQUJ2POII]/FNGN+:X"`[&@C9!P.AR32R:,DFCM
MIQN9\LP<SL0SEMV[//'4=,8JQ;6LT<4D=U>/=A^/G15P/3Y0*6EA75BI;ZK+
M,-))C0?;XB[XS\I"!N*:+K5/[?-D7M/LXB\[/EMOV[L8SNQGWIUCH@LYH'>\
MFN$M4*6Z.%`C!XZ@<G`QDU<^QI_:1OMS;S#Y6WMC.<T:`W%;$<-Z\FL75D44
M)!#%(&[DL7!_]!%4M/U'5+_R;V."W-C-*RA,D2J@)`<G.#R/NXZ'K6C'9)'J
M,]Z&8O/&D;*>@"EB,?\`?1JE!H*P7"%+R<6L4IFCM00%5CD]<9(R2<9Q1H%X
MC=1UM[+6+2T6.-H7(^T.S8,>\[8\#W8<U;FO'CU>VLPJE)HI'+=P5*X_]"JM
M>>'+"^:[DN(P\USC$Q4;XL`!=AQQ@C/UJ:]TR2ZN;>YBO9;::!&0,B*VX-C.
M00?[HH]T/=T(=>U2?2X[=HE1(Y9"LMQ)&SI",$@D+SR>,]!5K2[MK[3X[AWM
MY"^?GMWW(W/4'^G:DNK":>.`QW\T,\/_`"U0##Y&#N7&#_2ETW3HM,M3#&[.
M7D:1W;&6=CDG`X'/84:6!VY?,MTM%%20%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
B444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`'__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
